Acotiamide (monohydrochloride trihydrate)

Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC50 of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory [1][2][3].

Product Specifications

CAS Number

[773092-05-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/acotiamide-monohydrochloride-trihydrate.html

Purity

99.79

Solubility

DMSO : 116.67 mg/mL (ultrasonic) |H2O : 3.03 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CSC(NC(C2=CC(OC)=C(OC)C=C2O)=O)=N1)NCCN(C(C)C)C(C)C.[H]Cl.O.O.O

Molecular Formula

C21H37ClN4O8S

Molecular Weight

541.06

Precautions

H302, H315, H319

References & Citations

[1]Hiroshi Yamawaki, et al. Acotiamide attenuates central urocortin 2-induced intestinal inflammatory responses, and urocortin 2 treatment reduces TNF-α productions in LPS-stimulated macrophage cell lines. Neurogastroenterol Motil. 2020 Aug;32 (8) :e13813.|[2]Matsunaga Y, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011 Mar;336 (3) :791-800. |[3]Kazuyoshi Y oshii, et al. Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach. Pharmaceutical Research, 33 (2), 292–300.